Recent advancements in the understanding of pigmentary disorders are shifting the treatment paradigm toward targeted and combination therapies. In this Next Steps in Derm video interview, in conjunction with the Pigmentary Disorders Exchange Symposium, Zalfa A. Abdel-Malek, PhD, shares insights into the clinical development of MC1R agonist technology and its potential utility in dermatology.

‍

Dr. Abdel-Malek is professor emeritus of dermatology at the University of Cincinnati College of Medicine. Watch as she shares several evolving areas of research, including focusing MC1R agonist technology specifically toward vitiligo. Dr. Abdel-Malek explains how MC1R agonists aim to maintain and prolong repigmentation to address the clinical hurdle of pigmentation relapse. In addition, Dr. Abdel-Malek shares how MC1R agonists may offer photoprotection, repair UV-induced DNA damage, and help stabilize melanocytes.

‍

Dr. Abdel-Malek’s work shows the critical role of basic research in addressing unmet needs in dermatology. She emphasizes that bringing safe and effective clinical treatments to the bedside requires a continued commitment to bench research.